Dologel

Quick links to important sections

Dologel

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dologel

Property Description
Active ingredient Choline Salicylate and Lidocaine Hydrochloride
Form Topical Oral Gel
Pharmacological class NSAID and Local Anaesthetic
Type Combination medicine
Origin Synthetic

Dologel is a proprietary combination medicine formulated as a Topical Oral Gel, specifically engineered for localized application onto the tissues inside the mouth. This product is officially classified as a dual-action agent that integrates a Non-Steroidal Anti-Inflammatory Drug (NSAID) with a Local Anaesthetic. The preparation is designed as a semisolid gel for topical use only, focusing its action exclusively on the area of oral irritation rather than systemic distribution. This unique formulation is often positioned for the short-term management of common conditions, such as the localized pain associated with mouth ulcers in adults and adolescents.


Core Ingredients and Therapeutic Components

The core composition of Dologel is based on the combination of the active pharmaceutical ingredients Choline Salicylate and Lidocaine Hydrochloride. Choline Salicylate belongs to the salicylate class of drugs, which are widely recognized as NSAIDs and function to provide an anti-inflammatory effect by reducing swelling.

Complementing this, Lidocaine Hydrochloride (sometimes identified as Lignocaine Hydrochloride) acts as an amide-type Local Anaesthetic, responsible for the immediate analgesic effect by locally blocking pain signals. The formulation is considered a combination drug because it integrates these two distinct pharmacological mechanisms. This specific combination is clinically recognized for providing effective symptomatic relief by addressing both the sensory component of pain and the physical manifestation of inflammation.


General Purpose: Targeted Relief from Oral Discomfort

The general purpose of Dologel is to provide short-term relief by managing both the sensation of pain and the presence of localized inflammation within the oral cavity. The dual functionality of the Topical Oral Gel allows for the rapid mitigation of acute symptoms associated with various forms of oral irritation. Its nature ensures that the relief is both immediate and specifically localized, supporting patient comfort during activities like eating or speaking.

Regulatory References

  1. MedlinePlus Drug Information on Choline Salicylate
  2. NIH DailyMed Label for Lidocaine Hydrochloride

What side effects are possible with Dologel?

Possible Side Effects and Safety Information

The regulatory safety profile for this topical oral gel is organized by frequency and the organ systems affected, focusing primarily on localized effects and high-level systemic risks associated with the active components, Choline Salicylate and Lidocaine Hydrochloride.

Adverse Reaction Classifications

Side effects are often categorized in official documents by the likelihood of their occurrence:

  • Common Reactions: These are typically local effects experienced at the site of application and may include a transient burning sensation, irritation, or redness (erythema) of the oral mucosa.
  • Not Known Frequency: Other effects documented in post-marketing reports, such as taste disturbance or stomatitis (oral inflammation), may have a frequency that cannot be reliably estimated from available data.

Serious Adverse Reactions and Systemic Risk

Although adverse effects are usually localized, the official safety documentation addresses rare but serious concerns, primarily linked to hypersensitivity or excessive exposure:

  • Severe Hypersensitivity: Rare systemic reactions, including anaphylaxis or angioedema, are potential risks associated with both salicylates and local anaesthetics.
  • Systemic Toxicity: Serious effects, such as central nervous system disturbances or cardiovascular changes, are possible if the active ingredients are absorbed into the bloodstream in excessive amounts, usually associated with improper or prolonged use.

Population-Specific Safety Constraints

The regulatory label includes specific constraints for certain patient groups, particularly regarding the salicylate component:

  • Children and Adolescents: Due to the theoretical risk of Reye's syndrome, a serious condition, some regulatory bodies contraindicate the use of salicylate-containing oral gels in individuals under 16 years of age, especially when they have or are recovering from viral infections like chickenpox or influenza.
  • Pre-existing Conditions: Use is officially restricted or advised against in individuals with known hypersensitivity to the components or those with severely traumatized oral mucosa, which could increase systemic absorption.

Overdose and Emergency Response

Overdose and when to seek help

Overdose following excessive application or accidental ingestion of Dologel may lead to systemic toxicity from the active ingredients, Choline Salicylate and Lidocaine Hydrochloride. Regulatory documents describe two distinct toxicity profiles that require emergency intervention.

Documented Overdose Manifestations

Systemic Salicylate toxicity (salicylism) is documented to present with central nervous system disturbances such as tinnitus, confusion, and lethargy, alongside symptoms like nausea, vomiting, and rapid breathing (hyperpnea). Severe salicylate outcomes include life-threatening metabolic acidosis, pulmonary edema, and cerebral edema. The systemic toxicity profile for Lidocaine includes CNS effects like drowsiness, tremors, and seizures, potentially progressing to severe bradycardia, hypotension, and cardiac arrest.

Mandated Emergency Actions

Regulatory guidance strictly states that patients must seek immediate medical attention for any signs or symptoms of systemic toxicity. Urgent care is also required if severe complications arise, such as seizures, signs of methemoglobinemia (e.g., pale or blue skin coloration), or changes in consciousness. Management focuses on supportive care, ensuring adequate oxygenation, and may include procedures such as urinary alkalinization or hemodialysis for severe salicylate poisoning, as documented by official authorities. Official labeling notes that certain patients, including the elderly and those with hepatic impairment, may have an increased susceptibility to toxicity.

Therapeutic Uses of Dologel

What Dologel Treats: Main Uses and Benefits

The medication is considered relevant for easing symptoms related to inflammatory or irritative states. The active ingredient may be considered relevant for managing painful and inflammatory conditions primarily affecting these areas. The medication is generally applied across domains where additional symptomatic support is needed.

Dologel plays a role in managing symptoms across conditions characterized by acute or disruptive episodes, including common mouth ulcers (canker sores), pain associated with new dental appliances (like braces or dentures), and general oral soreness and inflammation.

The medication may be applied across domains where additional symptomatic support is needed to address symptoms related to physical discomfort, and supports the patient during difficult episodes by easing distress. The application is relevant when supportive symptom management is appropriate, as it:

“...contributes to improved comfort during periods of heightened symptoms.”

This supports the patient during episodes of heightened discomfort and may assist with maintaining functional stability and supports general well-being during symptomatic phases.

Quick Fact: Supportive Relief for Oral Discomfort

Eligibility and Restrictions for Use

The eligibility for using Dologel (Choline Salicylate and Lidocaine Hydrochloride) is strictly governed by regulatory status, primarily due to the salicylate component.

Contraindicated Populations

Use of this medicine is absolutely contraindicated for specific populations as stated in official labeling:

  • Age Restriction: Children and adolescents under the age of 16 must not use the gel, a precautionary measure linked to the theoretical risk of Reye's syndrome from salicylates [Source 2.4, 2.5].
  • Hypersensitivity: Patients with known allergy to lidocaine, choline salicylate, aspirin, other NSAIDs, or any of the gel's ingredients [Source 1.1, 2.2].
  • Pre-existing Conditions: Individuals with active or recurrent peptic ulceration (stomach ulcers) or pre-existing asthma or other chronic respiratory conditions [Source 1.1, 2.2].

Restricted and Conditional Use

Use requires special consideration and caution from a healthcare professional for the following groups:

  • Pregnancy and Lactation: Use is not recommended during pregnancy, and requires mandatory consultation with a doctor if breastfeeding [Source 1.1, 2.2].
  • Comorbidities: Caution is required for patients with diabetic conditions, or those with pre-existing kidney or liver impairment [Source 1.1, 3.3].
  • Viral Illness: The product must not be used by those with or recovering from viral illnesses such as chickenpox or influenza [Source 2.7].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Dologel, which contains Choline Salicylate (an NSAID) and Lidocaine Hydrochloride (a local anaesthetic), highlights specific interactions based on the pharmacological activity of its components. These interactions primarily involve pharmacodynamic effects rather than metabolic alteration, given the product’s topical oral route of administration.


Documented Pharmacodynamic Interactions

Interaction Entity Interaction Outcome Officially Documented
Anticoagulants (e.g., Warfarin) Co-administration may enhance the risk of bleeding due to the anti-platelet activity of the salicylate component.
Other Local Anaesthetics Co-administration may lead to an officially documented risk of additive systemic toxicity due to combined exposure to the Lidocaine component.
Uricosuric Agents (e.g., Probenecid) The salicylate component may inhibit the action of these medicines, officially reducing their therapeutic efficacy.

Population-Specific Caution

Regulatory information includes a note regarding a heightened potential for systemic exposure in infants if the recommended dosage limits are exceeded. This is a population-specific consideration related to exposure and toxicity, requiring strict adherence to prescribed application rules.

The official interaction profile is structured around these known substance class effects, detailing specific constraints and outcomes without providing clinical recommendations or instructions for use.

Mechanism of Action

Modulating Inflammatory Mediators via Enzyme Inhibition

This mechanistic domain covers the action of Choline Salicylate, which modulates the local inflammatory response by inhibiting Cyclooxygenase (COX) enzymes in oral tissues. This mechanism suppresses the synthesis of prostaglandins, leading to a physiological decrease in localized swelling and the modulation of peripheral nociceptor signaling.


Interruption of Nociceptive Signaling through Channel Blockade

This domain describes the rapid-onset action of Lidocaine Hydrochloride, which exerts its effect by physically blocking voltage-gated sodium channels ( NaV) on the membranes of sensory nerve cells. By preventing the influx of sodium ions, this mechanism stabilizes the nerve membrane and interrupts the electrical impulse necessary for the transmission of nociceptive signals, immediately suppressing localized afferent neural activity.


Dual-Pathway Mechanistic Synergy

This section addresses how the two components create a combined effect by targeting distinct yet complementary physiological processes. The enzyme inhibition mechanism (Choline Salicylate) affects the prostaglandin-driven inflammatory process, while the channel blockade mechanism (Lidocaine) affects the afferent sensory signal transmission, supporting a combined effect on both inflammatory mediators and neuronal electrical signaling.

Dosage and Administration Information

How Dologel is Used: Official Administration Guidelines

Administration scope Official Usage Detail
Route of administration Topical Oral Mucosal Use Only. The gel is applied directly to the site of irritation or the lesion inside the mouth.
Labeled dosing ranges and regimens Application involves using a small amount or thin film of the gel, often described as a pea-sized amount or approximately a half-inch ribbon, massaged gently into the affected area.
Frequency and schedule Use is intermittent and as-needed for acute symptoms, with a specified maximum application frequency. It may be applied up to three to eight times daily, depending on the specific product label, ensuring no more than one application every three hours.
Timing in relation to meals Patients are instructed to refrain from eating or drinking for a period (e.g., 30 to 60 minutes) following application to ensure the gel remains on the mucosal surface. Application is often timed after meals and before bedtime.
Age-group administration rules The regimen is generally for adults and adolescents. Use is typically not recommended for children and adolescents under the age of 16 due to the choline salicylate component.

Official Procedural Structure

The approved administration protocol requires a specific sequence of actions to ensure correct topical use. The official procedure is defined by regulatory documents as:

  1. Washing the hands thoroughly before initiating the application procedure.
  2. Applying the specified small amount of gel directly to the sore area using a clean fingertip or cotton bud.
  3. Washing the hands again immediately following the application procedure.

This framework mandates a topical oral route with a fixed dosage volume and strict limits on frequency, ensuring the product is administered only at the lesion site and is used exclusively for short-term courses as directed by the regulatory label. The product is not intended to be swallowed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dologel


Evidence for Use in Recurrent Aphthous Ulcers (Mouth Ulcers)

The primary research for the combination of Choline Salicylate and Lidocaine gel was explored using short-term randomized controlled trials (RCTs). These studies were designed to evaluate the product's use in adults diagnosed with minor, non-traumatic ulcers. Researchers examined measurements of physical discomfort, specifically the intensity of pain reported by patients, and monitored outcomes like ulcer size reduction and healing time over defined, short treatment intervals.

Trials reported measurements of pain intensity and healing patterns during the acute phase of the ulcer. However, long-term effects are not fully established regarding the overall impact on how often or how severely mouth ulcers recur. Furthermore, the evidence quality varies across studies, and research distinguishing the temporary sensory change provided by the local anesthetic component from the potential contribution of the salicylate component remains limited.


Evidence for Immediate Symptomatic Relief from Oral Lesions

Research was studied for its rapid effect, primarily involving very short-term, single-dose RCTs. These studies were applied in research contexts involving fluctuating or unstable symptoms from general oral lesions. The key outcome axes studies explored focused on the rapid onset of local sensory changes, or numbing, measuring changes in pain intensity typically within the first hour after a single application. These results apply only to the acute phase of symptom management.


Evidence in Specific or Vulnerable Populations

Research explored the use of the gel in specific or vulnerable populations and is limited. The main clinical trials were observed in adults only. Data for certain groups remain insufficient. For instance, there is limited specialized evidence concerning the use of this specific combination gel in older adults or those who have underlying health conditions. Due to regulatory considerations concerning the salicylate component (Choline Salicylate), studies were observed in specific age groups, and data for certain groups such as children and adolescents remain insufficient.

Key Studies & References

  1. Oral salicylate gels: not for use in those younger than age 16 years (MHRA Advice)
  2. Clinical Efficacy of a Topical Gel for the Treatment of Minor Oral Ulcers: A Triple-Blind Randomized Controlled Trial (Example of an oral ulcer RCT)
  3. Clinical study to know the efficacy of Amlexanox 5% with other topical Antiseptic, Analgesic and Anesthetic agents in treating minor RAS (RAS Comparative Trial including combination product)

Frequently Asked Questions (FAQ)

Common questions about Dologel (FAQ)

Q: Is Dologel intended only for mouth ulcers, or can it be used for other oral pain?

A: Official product information indicates that Dologel is used for the relief of localized pain and inflammation in the mouth, including mouth ulcers and general sore gums. Official guidance describes its use for various forms of oral mucosal irritation.

Q: Can Dologel be used for general gum irritation caused by dental issues?

A: According to regulatory labels, Dologel is commonly specified for the relief of sore gums and irritation caused by dentures. This use reflects the product's function as a localized pain reliever and anti-inflammatory agent for the oral cavity.

Q: How quickly can one expect Dologel to start providing pain relief?

A: Dologel contains Lidocaine, a local anaesthetic component known for its rapid action. The Lidocaine component acts quickly to stabilize nerve membranes, which is associated with a rapid onset of localized numbing and pain relief.

Q: Is a temporary numbing sensation on the application site considered normal when using Dologel?

A: The temporary numbing sensation is a characteristic outcome related to the action of the Lidocaine component, which is included to provide local pain relief. This agent temporarily blocks pain signals, leading to a loss of sensation at the application site.

Q: What is the expected timeframe for a mouth ulcer to heal while using Dologel?

A: Official product information generally suggests that Dologel is for short-term relief only. If an oral ulcer or its symptoms persist for longer than 7 days, or if the condition worsens, official guidance states that consultation with a doctor or dentist is necessary.

Q: Can Dologel be applied to sores caused by ill-fitting dentures or dental attachments?

A: Regulatory documentation often lists indications for Dologel that include the treatment of denture irritation. Regulatory documentation describes its use for localized sores or irritation caused by ill-fitting dental attachments.

Q: Is it common to experience dry mouth or changes in taste as a side effect of Dologel?

A: Official sources list taste disturbance as an adverse reaction that has been documented in post-marketing reports, though the frequency is often reported as 'Not Known.' Dry mouth is not specifically listed among the side effects in available official documentation.

Q: Is there any special caution for elderly patients who are considering using Dologel?

A: Regulatory documents for the salicylate component (a type of NSAID) include general precautions often applied to older adult populations. Official research specific to the Dologel combination gel in this age group is noted as being limited in some documents.

Q: What are the signs that someone might have used too much of the gel?

A: Signs of excessive absorption into the body, which is a risk of improper use, are described as potential systemic toxicity. Symptoms associated with potential systemic toxicity, as described in regulatory documents, may include signs of central nervous system involvement such as tinnitus (ringing in the ears), confusion, or dizziness.

Q: Is Dologel known to cause headaches or dizziness as a side effect?

A: Headaches are not specifically listed as a common side effect in official reports. However, in cases of improper use resulting in high systemic absorption, official documents note the possibility of central nervous system disturbances, which can include symptoms like dizziness or confusion.

Q: Are there known safety issues if Dologel is used for longer than the recommended short period?

A: Regulatory warnings state that the product should not be used for longer durations than recommended. The risk of the active ingredients being absorbed systemically is elevated with prolonged or excessive application, which may lead to more serious side effects.

Q: How long does the numbing or pain-relieving effect of Dologel typically last?

A: The pain-relieving effect comes from the Lidocaine component, a local anaesthetic with a short duration of action. The immediate numbing effect provides temporary relief, and the duration is short-lived, as is characteristic of local anaesthetics.

Q: Is there a concern about using Dologel simultaneously with other salicylate-containing products, like aspirin?

A: Official regulatory information advises that the combination of this product with acetylsalicylic acid (aspirin) or other salicylate-containing medicines requires guidance from a medical professional. This is a specific warning regarding the simultaneous use of these agents.

Q: What should be done if symptoms of the mouth ulcer persist after a few days of Dologel use?

A: Official product guidance establishes a requirement to seek consultation from a doctor or dentist if the mouth ulcer or its symptoms persist for more than seven days of use. Medical attention is also advised if symptoms worsen or if new symptoms, such as fever, appear.

Q: What is the difference between Dologel and Dologel-CT?

A: Regulatory sources describe both Dologel and Dologel-CT as combination gels containing the key active ingredients Choline Salicylate and Lidocaine for pain and inflammation relief. Differences between regional versions may exist in the specific antiseptic agent included or the excipients in the formulation.

Q: Is Dologel intended for use on cold sores (herpes labialis)?

A: Dologel is officially indicated for the management of pain associated with mouth ulcers (aphthous ulcers) and other types of oral irritation. The regulatory label does not include the treatment of viral cold sores (herpes labialis).

Q: What is the maximum duration of use for Dologel described in product information?

A: Official product information emphasizes that Dologel is intended only for short-term use. Regulatory guidelines stipulate that if the symptoms for which the gel is being used do not clear up after seven days, consultation with a medical professional is necessary.

Q: Is there an established interaction between Dologel and alcohol consumption?

A: Official regulatory texts often advise caution regarding alcohol consumption while using Dologel. Official guidance generally suggests avoiding alcohol during the period of use.

Q: Does the formulation of Dologel contain any sugar or alcohol that might affect blood sugar levels?

A: Regulatory documents list the excipients (non-active ingredients) in the gel. While the product is typically described as sodium-free, the formulation may contain small amounts of alcohol (such as anisyl alcohol) used in the fragrance or as a preservative.

Q: Are there studies on the use of Dologel for pain caused by orthodontic braces?

A: Official sources or labels for Dologel often list its use for sore gums or irritation caused by dental appliances in the mouth. This indication is consistent with the product's function to relieve localized pain caused by physical irritation of the oral mucosa.

Q: Can the application of Dologel cause local swelling at the ulcer site?

A: The product is a combination of an anti-inflammatory and an anaesthetic, intended to reduce inflammation. However, official safety documentation lists localized reactions such as irritation and redness of the oral mucosa at the site of application.

Q: Is Dologel considered habit-forming or addictive?

A: Official product quick tips and safety information commonly state that Dologel is not considered habit-forming or addictive.

Q: Can Dologel affect the results of certain lab tests, as described in product information?

A: Regulatory texts for the salicylate component often warn that it may interact with certain lab tests. This interaction can lead to false results in specific urine tests for sugar or other compounds, as noted in the product information.

Q: Is there a known interaction between Dologel and antacids?

A: Regulatory information for the Choline Salicylate component often notes an interaction with certain antacids. This interaction may result in a decreased effectiveness of the Choline Salicylate component.

Q: What is the recommended advice if a large amount of Dologel is accidentally swallowed?

A: Dologel is strictly for topical use and is not intended for swallowing. If a large amount is accidentally swallowed, official regulatory documents describe the symptoms of overdose related to systemic toxicity of its components, and official guidance mandates immediate emergency medical attention.

How should Dologel be stored and disposed of?

How to Store and Dispose of Dologel?

The storage and disposal of Dologel Topical Oral Gel (Choline Salicylate and Lidocaine Hydrochloride) must strictly adhere to regulatory labeling requirements.


Storage Conditions

Dologel must be stored at a temperature below 30 C or within the specified range of 10 C to 25 C. The container should be kept tightly closed in a clean, dry place and away from sunlight. Do not use the gel after the expiry date has passed.


Safety and Disposal

It is mandatory to keep the medicine out of the sight and reach of children and pets at all times. Unused or expired Dologel must be disposed of according to the instructions on the pack or label, ensuring the discarded product is not consumed by others.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dologel found in:

A-Z Index: